Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.
In PLoS ONE, 2005
... weight fibroblast growth factor (lo-FGF Santa Cruz Biotechnology), HO-1 (Stressgen, Ann Arbor, MI, USA), cytochrome-c, HDAC5 (Cell Signaling, Danvers, MA, USA), HDAC1 ...
Mysteries of metals in metalloenzymes.
Los Angeles, United States. In Acc Chem Res, 21 Nov 2014
For example, histone deacetylase 8 naturally operates with Zn(2+) in the active site but becomes much more active with Fe(2+).
Novel Approaches in Anaplastic Thyroid Cancer Therapy.
Madison, United States. In Oncologist, 26 Oct 2014
This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways.
Synthesis and metabolic studies of 1α,2α,25-, 1α,4α,25- and 1α,4β,25-trihydroxyvitamin D3.
Tokyo, Japan. In J Steroid Biochem Mol Biol, 25 Oct 2014
We first chemically synthesized 1α,2α,25-trihydroxyvitamin D3 [1α,2α,25(OH)3D3] to study its VDR binding affinity because this metabolite is a product of recombinant human CYP3A4 catalysis when 2α-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3 (O2C3), a more potent vitamin D receptor (VDR) binder than 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], is used as the substrate.
Chromatin repressive complexes in stem cells, development, and cancer.
Copenhagen, Denmark. In Cell Stem Cell, Jul 2014
Here, we review the roles of the polycomb repressive complexes, PRC1 and PRC2, and the HDAC1- and HDAC2-containing complexes, NuRD, Sin3, and CoREST, in stem cells, development, and cancer, as well as the ongoing efforts to develop therapies targeting these complexes in human cancer.
Ataxia-telangiectasia: future prospects.
Ad Dammām, Saudi Arabia. In Appl Clin Genet, Dec 2013
As of now, apart from glucocorticoids, use of histone deacetylase inhibitors/EZH2 to minimize effect of the absence of ATM, looks more promising.
Micro-RNA-632 downregulates DNAJB6 in breast cancer.
Mobile, United States. In Lab Invest, 2012
miR-632 is a potentially important epigenetic regulator of DNAJB6, which contributes to the downregulation of DNAJB6 and plays a supportive role in malignant progression